Click here to get full coverage on MBX (NASDAQ: MBX) Richard Bartram lists multiple May sales, June option exercise - Stock Titan

MBX (NASDAQ: MBX) Richard Bartram lists multiple May sales, June option exercise  Stock Titan

MBX (NASDAQ: MBX) Richard Bartram lists multiple May sales, June option exercise - Stock Titan

Click here to get full coverage on MBX Biosciences: In Danger Of Being Outpaced By Rivals - Rating Downgrade (NASDAQ:MBX) - Seeking Alpha

MBX Biosciences: In Danger Of Being Outpaced By Rivals - Rating Downgrade (NASDAQ:MBX)  Seeking Alpha

MBX Biosciences: In Danger Of Being Outpaced By Rivals - Rating Downgrade (NASDAQ:MBX) - Seeking Alpha

Click here to get full coverage on Should Upcoming Canvuparatide Phase 2 Data Presentations Require Action From MBX Biosciences (MBX) Investors? - simplywall.st

Should Upcoming Canvuparatide Phase 2 Data Presentations Require Action From MBX Biosciences (MBX) Investors?  simplywall.st

Should Upcoming Canvuparatide Phase 2 Data Presentations Require Action From MBX Biosciences (MBX) Investors? - simplywall.st

Click here to get full coverage on MBX: All director and auditor proposals were approved by stockholders at the annual meeting - TradingView

MBX: All director and auditor proposals were approved by stockholders at the annual meeting  TradingView

MBX: All director and auditor proposals were approved by stockholders at the annual meeting - TradingView

Click here to get full coverage on MBX Biosciences CFO Shift Puts Funding And Execution In Focus - Yahoo Finance

MBX Biosciences CFO Shift Puts Funding And Execution In Focus  Yahoo Finance

MBX Biosciences CFO Shift Puts Funding And Execution In Focus - Yahoo Finance

Click here to get full coverage on MBX Biosciences to Present at the Jefferies 2026 Global Healthcare Conference in New York City - GlobeNewswire

MBX Biosciences to Present at the Jefferies 2026 Global Healthcare Conference in New York City  GlobeNewswire

MBX Biosciences to Present at the Jefferies 2026 Global Healthcare Conference in New York City - GlobeNewswire

Click here to get full coverage on Chief Medical Officer Sells MBX for $2.7 Million After Monster 2026 Run - The Motley Fool

Chief Medical Officer Sells MBX for $2.7 Million After Monster 2026 Run  The Motley Fool

Chief Medical Officer Sells MBX for $2.7 Million After Monster 2026 Run - The Motley Fool

Click here to get full coverage on MBX Biosciences (MBX) director and 10% owner receives 12,500 stock options grant - Stock Titan

MBX Biosciences (MBX) director and 10% owner receives 12,500 stock options grant  Stock Titan

MBX Biosciences (MBX) director and 10% owner receives 12,500 stock options grant - Stock Titan

Click here to get full coverage on MBX: Directors and auditor ratified; no shareholder questions addressed - TradingView

MBX: Directors and auditor ratified; no shareholder questions addressed  TradingView

MBX: Directors and auditor ratified; no shareholder questions addressed - TradingView

Click here to get full coverage on MBX Biosciences to Host Virtual Investor Event to Discuss Once-Weekly Canvuparatide Presentations at ENDO 2026 - Yahoo Finance Singapore

MBX Biosciences to Host Virtual Investor Event to Discuss Once-Weekly Canvuparatide Presentations at ENDO 2026  Yahoo Finance Singapore

MBX Biosciences to Host Virtual Investor Event to Discuss Once-Weekly Canvuparatide Presentations at ENDO 2026 - Yahoo Finance Singapore

Click here to get full coverage on MBX Biosciences (MBX) director granted 12,500 stock options at $30.91 strike - Stock Titan

MBX Biosciences (MBX) director granted 12,500 stock options at $30.91 strike  Stock Titan

MBX Biosciences (MBX) director granted 12,500 stock options at $30.91 strike - Stock Titan

Click here to get full coverage on MB elects two Class II directors to three-year terms through 2029 - TradingView

MB elects two Class II directors to three-year terms through 2029  TradingView

MB elects two Class II directors to three-year terms through 2029 - TradingView

Click here to get full coverage on Insider Stock Buying Reaches US$1.06m On MBX Biosciences - Yahoo Finance

Insider Stock Buying Reaches US$1.06m On MBX Biosciences  Yahoo Finance

Insider Stock Buying Reaches US$1.06m On MBX Biosciences - Yahoo Finance

Click here to get full coverage on MBX Biosciences (MBX) grants stock options to director Ora Pescovitz - Stock Titan

MBX Biosciences (MBX) grants stock options to director Ora Pescovitz  Stock Titan

MBX Biosciences (MBX) grants stock options to director Ora Pescovitz - Stock Titan

Click here to get full coverage on MBX Biosciences (MBX) director receives grant of 12,500 stock options at $30.91 - Stock Titan

MBX Biosciences (MBX) director receives grant of 12,500 stock options at $30.91  Stock Titan

MBX Biosciences (MBX) director receives grant of 12,500 stock options at $30.91 - Stock Titan

Click here to get full coverage on MBX Biosciences (MBX) director receives stock options for 12,500 shares - Stock Titan

MBX Biosciences (MBX) director receives stock options for 12,500 shares  Stock Titan

MBX Biosciences (MBX) director receives stock options for 12,500 shares - Stock Titan

Click here to get full coverage on MBX Biosciences (MBX) director Steven Ryder granted 12,500 stock options - Stock Titan

MBX Biosciences (MBX) director Steven Ryder granted 12,500 stock options  Stock Titan

MBX Biosciences (MBX) director Steven Ryder granted 12,500 stock options - Stock Titan

Click here to get full coverage on MBX Biosciences (MBX) director awarded 12,500 stock options - Stock Titan

MBX Biosciences (MBX) director awarded 12,500 stock options  Stock Titan

MBX Biosciences (MBX) director awarded 12,500 stock options - Stock Titan

Click here to get full coverage on MBX Biosciences (NASDAQ: MBX) 2026 meeting backs directors and Ernst & Young - Stock Titan

MBX Biosciences (NASDAQ: MBX) 2026 meeting backs directors and Ernst & Young  Stock Titan

MBX Biosciences (NASDAQ: MBX) 2026 meeting backs directors and Ernst & Young - Stock Titan

Click here to get full coverage on MBX Phase 3 Plans And New CBO Sharpen Rare Disease Focus - Yahoo Finance

MBX Phase 3 Plans And New CBO Sharpen Rare Disease Focus  Yahoo Finance

MBX Phase 3 Plans And New CBO Sharpen Rare Disease Focus - Yahoo Finance

Click here to get full coverage on MBX Biosciences (MBX) Is Down 9.7% After Goldman Sell Call and MPM Exit - What's Changed - Yahoo Finance

MBX Biosciences (MBX) Is Down 9.7% After Goldman Sell Call and MPM Exit - What's Changed  Yahoo Finance

MBX Biosciences (MBX) Is Down 9.7% After Goldman Sell Call and MPM Exit - What's Changed - Yahoo Finance

Click here to get full coverage on MBX: Once-weekly PTH and monthly obesity therapies show strong clinical promise and market potential - TradingView

MBX: Once-weekly PTH and monthly obesity therapies show strong clinical promise and market potential  TradingView

MBX: Once-weekly PTH and monthly obesity therapies show strong clinical promise and market potential - TradingView

Click here to get full coverage on MBX: Once-weekly PTH and monthly obesity therapies show strong promise for efficacy, tolerability, and market impact - TradingView

MBX: Once-weekly PTH and monthly obesity therapies show strong promise for efficacy, tolerability, and market impact  TradingView

MBX: Once-weekly PTH and monthly obesity therapies show strong promise for efficacy, tolerability, and market impact - TradingView

Click here to get full coverage on Precision Trading with MBX Group (MBX) Risk Zones - Stock Traders Daily

Precision Trading with MBX Group (MBX) Risk Zones  Stock Traders Daily

Precision Trading with MBX Group (MBX) Risk Zones - Stock Traders Daily

Click here to get full coverage on MBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights - Yahoo Finance

MBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights  Yahoo Finance

MBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights - Yahoo Finance

Click here to get full coverage on Does MBX (MBX) Options-Driven Breakout Reveal Deeper Shifts In Its Investment Narrative? - Yahoo Finance

Does MBX (MBX) Options-Driven Breakout Reveal Deeper Shifts In Its Investment Narrative?  Yahoo Finance

Does MBX (MBX) Options-Driven Breakout Reveal Deeper Shifts In Its Investment Narrative? - Yahoo Finance

Click here to get full coverage on Assessing MBX Biosciences (MBX) Valuation After A 261% One Year Total Shareholder Return - Yahoo Finance

Assessing MBX Biosciences (MBX) Valuation After A 261% One Year Total Shareholder Return  Yahoo Finance

Assessing MBX Biosciences (MBX) Valuation After A 261% One Year Total Shareholder Return - Yahoo Finance

Click here to get full coverage on MBX Capital’s fund for early-stage startups passes $100 million - The Pharma Letter

MBX Capital’s fund for early-stage startups passes $100 million  The Pharma Letter

MBX Capital’s fund for early-stage startups passes $100 million - The Pharma Letter

Click here to get full coverage on MBX Biosciences announces CFO transition and new lease for Massachusetts facility - Investing.com

MBX Biosciences announces CFO transition and new lease for Massachusetts facility  Investing.com

MBX Biosciences announces CFO transition and new lease for Massachusetts facility - Investing.com

Click here to get full coverage on MBX Biosciences to Provide 2026 Outlook and Business Update at 44th Annual J.P. Morgan Healthcare Conference - Yahoo Finance

MBX Biosciences to Provide 2026 Outlook and Business Update at 44th Annual J.P. Morgan Healthcare Conference  Yahoo Finance

MBX Biosciences to Provide 2026 Outlook and Business Update at 44th Annual J.P. Morgan Healthcare Conference - Yahoo Finance

Click here to get full coverage on MBX Biosciences Calls 2026 “Pivotal” With Phase 3 Plans, Obesity Program, and $460M Cash Runway - Yahoo Finance

MBX Biosciences Calls 2026 “Pivotal” With Phase 3 Plans, Obesity Program, and $460M Cash Runway  Yahoo Finance

MBX Biosciences Calls 2026 “Pivotal” With Phase 3 Plans, Obesity Program, and $460M Cash Runway - Yahoo Finance

Click here to get full coverage on Number of shareholders of MBX Biosciences, Inc. – NASDAQ:MBX - TradingView

Number of shareholders of MBX Biosciences, Inc. – NASDAQ:MBX  TradingView

Number of shareholders of MBX Biosciences, Inc. – NASDAQ:MBX - TradingView

Click here to get full coverage on $MBX stock is down 10% today. Here's what we see in our data. - Quiver Quantitative

$MBX stock is down 10% today. Here's what we see in our data.  Quiver Quantitative

$MBX stock is down 10% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on MBX's weekly hypoparathyroidism drug hits key goals in Phase II - FirstWord Pharma

MBX's weekly hypoparathyroidism drug hits key goals in Phase II  FirstWord Pharma

MBX's weekly hypoparathyroidism drug hits key goals in Phase II - FirstWord Pharma

Click here to get full coverage on MBX Biosciences Advances Obesity And PBH Pipeline As Shares Surge - simplywall.st

MBX Biosciences Advances Obesity And PBH Pipeline As Shares Surge  simplywall.st

MBX Biosciences Advances Obesity And PBH Pipeline As Shares Surge - simplywall.st

Click here to get full coverage on MBX Biosciences Provides Obesity Portfolio Update Including Initial Phase 1 Data for MBX 4291 Supporting Potential for Once-Monthly Dosing - Yahoo Finance

MBX Biosciences Provides Obesity Portfolio Update Including Initial Phase 1 Data for MBX 4291 Supporting Potential for Once-Monthly Dosing  Yahoo Finance

MBX Biosciences Provides Obesity Portfolio Update Including Initial Phase 1 Data for MBX 4291 Supporting Potential for Once-Monthly Dosing - Yahoo Finance

Click here to get full coverage on MBX hormone replacement shows efficacy in mid-stage study - statnews.com

MBX hormone replacement shows efficacy in mid-stage study  statnews.com

MBX hormone replacement shows efficacy in mid-stage study - statnews.com

Click here to get full coverage on Wausau acquires contaminated MBX riverfront property for redevelopment - Wausau Pilot & Review

Wausau acquires contaminated MBX riverfront property for redevelopment  Wausau Pilot & Review

Wausau acquires contaminated MBX riverfront property for redevelopment - Wausau Pilot & Review

Click here to get full coverage on MBX Biosciences (MBX) Is Down 20.8% After Wider Loss, Obesity Data And New CCO - Has The Bull Case Changed? - simplywall.st

MBX Biosciences (MBX) Is Down 20.8% After Wider Loss, Obesity Data And New CCO - Has The Bull Case Changed?  simplywall.st

MBX Biosciences (MBX) Is Down 20.8% After Wider Loss, Obesity Data And New CCO - Has The Bull Case Changed? - simplywall.st

Click here to get full coverage on 3 Overlooked Stocks Set to Soar in 2026 - AOL.com

3 Overlooked Stocks Set to Soar in 2026  AOL.com

3 Overlooked Stocks Set to Soar in 2026 - AOL.com

Click here to get full coverage on MBX Biosciences Appoints Karen Basbaum as Chief Business Officer - Yahoo Finance

MBX Biosciences Appoints Karen Basbaum as Chief Business Officer  Yahoo Finance

MBX Biosciences Appoints Karen Basbaum as Chief Business Officer - Yahoo Finance

Click here to get full coverage on CORRECTING & REPLACING -- MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism - Yahoo Finance

CORRECTING & REPLACING -- MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism  Yahoo Finance

CORRECTING & REPLACING -- MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism - Yahoo Finance

Click here to get full coverage on MBX Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

MBX Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)  GlobeNewswire

MBX Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Click here to get full coverage on MBX Biosciences (MBX) Faces Platform Validation Challenge as Near-Term Hypoglycemia Data Catalyst in Q2 2026 May Lack Differentiation - Yahoo Finance

MBX Biosciences (MBX) Faces Platform Validation Challenge as Near-Term Hypoglycemia Data Catalyst in Q2 2026 May Lack Differentiation  Yahoo Finance

MBX Biosciences (MBX) Faces Platform Validation Challenge as Near-Term Hypoglycemia Data Catalyst in Q2 2026 May Lack Differentiation - Yahoo Finance

Click here to get full coverage on Technical Reactions to MBX Trends in Macro Strategies - Stock Traders Daily

Technical Reactions to MBX Trends in Macro Strategies  Stock Traders Daily

Technical Reactions to MBX Trends in Macro Strategies - Stock Traders Daily

Click here to get full coverage on MBX Biosciences (Nasdaq: MBX) adds Burlington lab, names interim CFO - Stock Titan

MBX Biosciences (Nasdaq: MBX) adds Burlington lab, names interim CFO  Stock Titan

MBX Biosciences (Nasdaq: MBX) adds Burlington lab, names interim CFO - Stock Titan

Click here to get full coverage on MBX highlights early data for monthly obesity drug MBX-4291 - BioWorld News

MBX highlights early data for monthly obesity drug MBX-4291  BioWorld News

MBX highlights early data for monthly obesity drug MBX-4291 - BioWorld News

Click here to get full coverage on Weekly drug for hormone disorder heads to 160-patient trial - Stock Titan

Weekly drug for hormone disorder heads to 160-patient trial  Stock Titan

Weekly drug for hormone disorder heads to 160-patient trial - Stock Titan

Click here to get full coverage on MBX Biosciences Announces Pricing of Upsized Public Offering - Yahoo Finance

MBX Biosciences Announces Pricing of Upsized Public Offering  Yahoo Finance

MBX Biosciences Announces Pricing of Upsized Public Offering - Yahoo Finance

Click here to get full coverage on MBX Biosciences to Present at the Jefferies 2026 Global Healthcare Conference in New York City - Sahm

MBX Biosciences to Present at the Jefferies 2026 Global Healthcare Conference in New York City  Sahm

MBX Biosciences to Present at the Jefferies 2026 Global Healthcare Conference in New York City - Sahm

Click here to get full coverage on Insider Purchase: President & CEO of $MBX Buys 20,000 Shares - Quiver Quantitative

Insider Purchase: President & CEO of $MBX Buys 20,000 Shares  Quiver Quantitative

Insider Purchase: President & CEO of $MBX Buys 20,000 Shares - Quiver Quantitative

Click here to get full coverage on Aaron Wealth Makes a Big Bet on MBX Biosciences With a 1.1 Million Share Purchase - The Motley Fool

Aaron Wealth Makes a Big Bet on MBX Biosciences With a 1.1 Million Share Purchase  The Motley Fool

Aaron Wealth Makes a Big Bet on MBX Biosciences With a 1.1 Million Share Purchase - The Motley Fool

Click here to get full coverage on New MBX business chief gets 130,000 stock options at $32.29 - Stock Titan

New MBX business chief gets 130,000 stock options at $32.29  Stock Titan

New MBX business chief gets 130,000 stock options at $32.29 - Stock Titan

Click here to get full coverage on She helped sell a biotech to Roche — now she’s joining MBX - Stock Titan

She helped sell a biotech to Roche — now she’s joining MBX  Stock Titan

She helped sell a biotech to Roche — now she’s joining MBX - Stock Titan

Click here to get full coverage on MBX obesity drug targets monthly dosing after 7% Phase 1 weight loss - Stock Titan

MBX obesity drug targets monthly dosing after 7% Phase 1 weight loss  Stock Titan

MBX obesity drug targets monthly dosing after 7% Phase 1 weight loss - Stock Titan

Click here to get full coverage on MBX BIOSCIENCES Earnings Results: $MBX Reports Quarterly Earnings - Quiver Quantitative

MBX BIOSCIENCES Earnings Results: $MBX Reports Quarterly Earnings  Quiver Quantitative

MBX BIOSCIENCES Earnings Results: $MBX Reports Quarterly Earnings - Quiver Quantitative

Click here to get full coverage on Drug maker maps out once-monthly obesity shots and hormone disorder trial - Stock Titan

Drug maker maps out once-monthly obesity shots and hormone disorder trial  Stock Titan

Drug maker maps out once-monthly obesity shots and hormone disorder trial - Stock Titan

Click here to get full coverage on EX-99.1 - SEC.gov

EX-99.1 - SEC.gov

Click here to get full coverage on MBX Biosciences (MBX) CMO exercises options and sells 70,003 shares under 10b5-1 plan - Stock Titan

MBX Biosciences (MBX) CMO exercises options and sells 70,003 shares under 10b5-1 plan  Stock Titan

MBX Biosciences (MBX) CMO exercises options and sells 70,003 shares under 10b5-1 plan - Stock Titan

Click here to get full coverage on MBX Biosciences, Inc. ($MBX) CEO 2025 Pay Revealed - Quiver Quantitative

MBX Biosciences, Inc. ($MBX) CEO 2025 Pay Revealed  Quiver Quantitative

MBX Biosciences, Inc. ($MBX) CEO 2025 Pay Revealed - Quiver Quantitative

Click here to get full coverage on Wausau committee tables forgivable-loan offer for MBX site amid transparency concerns - Wausau Pilot & Review

Wausau committee tables forgivable-loan offer for MBX site amid transparency concerns  Wausau Pilot & Review

Wausau committee tables forgivable-loan offer for MBX site amid transparency concerns - Wausau Pilot & Review

Click here to get full coverage on Insider sale notice: 15,000 shares planned | MBX SEC Filing - Form 144 - Stock Titan

Insider sale notice: 15,000 shares planned | MBX SEC Filing - Form 144  Stock Titan

Insider sale notice: 15,000 shares planned | MBX SEC Filing - Form 144 - Stock Titan

Click here to get full coverage on Why MBX Biosciences (MBX) Is Up 12.7% After Strong Phase II Data and Equity Offering News - Yahoo Finance

Why MBX Biosciences (MBX) Is Up 12.7% After Strong Phase II Data and Equity Offering News  Yahoo Finance

Why MBX Biosciences (MBX) Is Up 12.7% After Strong Phase II Data and Equity Offering News - Yahoo Finance

Click here to get full coverage on $MBX stock is down 16% today. Here's what we see in our data. - Quiver Quantitative

$MBX stock is down 16% today. Here's what we see in our data.  Quiver Quantitative

$MBX stock is down 16% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on MBX (MBX) Rule 144: Bartram sold 21,484 shares; Fidelity lists 5,000 - Stock Titan

MBX (MBX) Rule 144: Bartram sold 21,484 shares; Fidelity lists 5,000  Stock Titan

MBX (MBX) Rule 144: Bartram sold 21,484 shares; Fidelity lists 5,000 - Stock Titan

Click here to get full coverage on Former Alnylam, Pfizer executive joins MBX as commercial chief - Stock Titan

Former Alnylam, Pfizer executive joins MBX as commercial chief  Stock Titan

Former Alnylam, Pfizer executive joins MBX as commercial chief - Stock Titan

Click here to get full coverage on MBX Biosciences Announces Once-Weekly Canvuparatide - GlobeNewswire

MBX Biosciences Announces Once-Weekly Canvuparatide  GlobeNewswire

MBX Biosciences Announces Once-Weekly Canvuparatide - GlobeNewswire

Click here to get full coverage on MBX (NASDAQ) affiliate sells multiple tranches of shares in Rule 144 notices - Stock Titan

MBX (NASDAQ) affiliate sells multiple tranches of shares in Rule 144 notices  Stock Titan

MBX

Price Chart

Key Statistics

Technicals

About MBX

Latest News

MBX (NASDAQ: MBX) Richard Bartram lists multiple May sales, June option exercise - Stock Titan

MBX Biosciences: In Danger Of Being Outpaced By Rivals - Rating Downgrade (NASDAQ:MBX) - Seeking Alpha

Should Upcoming Canvuparatide Phase 2 Data Presentations Require Action From MBX Biosciences (MBX) Investors? - simplywall.st

Advanced Charts

Top Gainers

Top Losers